Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Qutenza in Patients With Head and Neck Cancer in Remission and With Sequelae Neuropathic Pain
NCT04704453Phase 2Completed
- Sponsor
- Institut Claudius Regaud
- Start
- Apr 2021
- Primary completion
- Apr 2025
- Modality
- Transdermal Patches, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of capsaicin 8% patch in neuropathic pain (2 arms), sponsored by Institut Claudius Regaud. Primary endpoint: Rate of patients with a decrease in average pain over the last 24 hours by 2 points at 9 months. Started Apr 2021; status: completed.
02
Drugs
capsaicin 8% patch
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT04704453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04704453.